Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France)

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01742741
• Other study ID #: France
• Secondary ID: JDRF 22-2011-649
• Status: Completed
• Phase: N/A
• First received: December 3, 2012
• Last updated: September 6, 2013
• Start date: May 2013
• Est. completion date: May 2013

Study information

• Verified date: September 2013
• Source: University of Virginia
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

An unblinded, randomized, cross-over design with each patient participating in two 40-hour outpatient admissions: (a) Experimental involving automated Control-to-Range (CTR) and (b) Control using Continuous Glucose Monitor (CGM)-augmented insulin pump treatment outside of a hospital based clinical research center.

Description:

The principal goal is to validate a smart phone-based control-to-range (CTR) system for ambulatory use and to estimate the effect of CTR vs. sensor-augmented pump therapy, thereby providing justification for further larger home-based trials of CTR.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: May 2013
• Est. primary completion date: May 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 64 Years

Eligibility

Inclusion Criteria:

1. =21 and <65 years old.

2. Clinical diagnosis of type 1 diabetes mellitus. For an individual to be enrolled at least one criterion from each list must be met.

o Criteria for documented hyperglycemia (at least 1 must be met): i. Fasting glucose =126 mg/dL - confirmed ii. Two-hour Oral Glucose Tolerance Test (OGTT) glucose =200 mg/dL - confirmed iii. HbA1c =6.5% documented - confirmed iv. Random glucose =200 mg/dL with symptoms v. No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes

o Criteria for requiring insulin at diagnosis (1 must be met): i. Participant required insulin at diagnosis and continually thereafter ii. Participant did not start insulin at diagnosis but upon investigator review likely needed insulin (significant hyperglycemia that did not respond to oral agents) and did require insulin eventually and used continually iii. Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies - consistent with latent autoimmune diabetes in adults (LADA) and did require insulin eventually and used continually

3. Use of an insulin pump to treat his/her diabetes for at least 1 year.

4. Familiarity with a bolus calculator with the current insulin pump with pre-defined parameters for carbohydrate (CHO) ratio, insulin sensitivity factor (ISF), target glucose and active insulin.

5. HbA1c <9% as measured with DCA2000 or equivalent device.

6. Not currently known to be pregnant, breast feeding, or intending to become pregnant (females).

7. Demonstration of proper mental status and cognition for the study.

8. Willingness to avoid consumption of acetaminophen-containing products during the study interventions involving CGM use.

9. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, have stability on the medication for at least 2 months prior to enrollment in the study.

Exclusion Criteria:

1. Severe hypoglycemia resulting in seizure, loss of consciousness, or diabetic ketoacidosis within the 12 months prior to enrollment.

2. Pregnancy; breast feeding, or intention of becoming pregnant.

3. Uncontrolled arterial hypertension (Resting diastolic blood pressure >90 mmHg and/or systolic blood pressure >160 mmHg).

4. Conditions which may increase the risks associated with possible hypoglycemia, such as any active cardiac disorder/arrhythmia, uncontrolled coronary artery disease during the previous year (e.g. history of myocardial infarction, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented EKG changes, or positive stress test or catheterization with coronary blockages >50%), congestive heart failure, history of cerebrovascular event, seizure disorder, syncope, adrenal insufficiency, neurologic disease or atrial fibrillation.

5. Self-reported hypoglycemia unawareness.

6. History of a systemic or deep tissue infection with methicillin-resistant staph aureus or Candida albicans.

7. Use of a device that may pose electromagnetic compatibility issues and/or radiofrequency interference with the CGM (implantable cardioverter-defibrillator, electronic pacemaker, neurostimulator, intrathecal pump, and cochlear implants).

8. Anticoagulant therapy other than aspirin.

9. Oral steroids.

10. Medical condition requiring use of an acetaminophen-containing medication that cannot be withheld for the study admissions.

11. Psychiatric disorders that would interfere with study tasks (e.g. inpatient psychiatric treatment within 6 months prior to enrollment).

12. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

13. Known current or recent alcohol or drug abuse.

14. Medical conditions that would make operating a CGM, the DiAs cell phone or insulin pump difficult (e.g. blindness, severe arthritis, immobility).

15. Any skin condition that prevents sensor or pump placement on the abdomen or arm (e.g. bad sunburn, pre-existing dermatitis, intertrigo, psoriasis, extensive scarring, cellulitis).

16. In adherence with the One Touch Ultra 2 User Guide, subjects with hematocrit levels less than 30% and above 55% will be excluded.

17. Impaired hepatic function measured as alanine aminotransferase or aspartate aminotransferase =three times the upper reference limit.

18. Impaired renal function measured as creatinine >1.2 times above the upper limit of normal.

19. Uncontrolled microvascular (diabetic) complications, such as current proliferative diabetic retinopathy or macular edema, known diabetic nephropathy (other than microalbuminuria with normal creatinine) or neuropathy requiring treatment.

20. Active gastroparesis requiring current medical therapy.

21. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study.

22. Uncontrolled thyroid disease.

23. Known bleeding diathesis or dyscrasia.

24. Known allergy to medical adhesives, components of the insulin pump insertion set or continuous glucose monitor sensor.

25. Active enrollment in another clinical trial.

26. Use of anti-diabetic agents other than continuous subcutaneous insulin infusion (CSII) including long-acting insulin, intermediate-acting insulin, metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-IV inhibitors, glucagon-like peptide 1 agonists, and alpha-glucosidase inhibitors

27. Subjects with basal rates less than 0.01U/hr.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Device:
• Diabetes Assistant (DiAs)
A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.

Locations

Country	Name	City	State
France	Centre d'Investigation Clinique CHU Montipellier	Montpellier

Sponsors (4)

Lead Sponsor	Collaborator
University of Virginia	Juvenile Diabetes Research Foundation, University of California, Santa Barbara, University of Padova

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Patient comfort with the Diabetes Assistant (DiAs) user interface		40 hours	No
Other	Reliability of DiAs remote monitoring	Assess the DiAs remote monitoring by medical personnel/technicians to confirm appropriate functioning outside of the hospital setting.	40 hours	No
Other	Reliability of inter-device connections between DiAs and the CGM and between DiAs and the insulin pump.	Assess the functioning of the connections between DiAs, the continuous glucose sensor, and the insulin pump.	40 hours	Yes
Primary	Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment in an outpatient setting.	The investigators expect that compared to CGM-augmented insulin pump treatment, CTR will result in moderate effect size of approximately 0.4, in terms of reduction of the overnight risk for hypoglycemia as measured by the Low Blood Glucose Index computed from retrofitted CGM data. This effect is not expected to be statistically significant with the anticipated sample size but will be used to inform power analysis for the subsequent multi-center trial of CTR at home.	40 hours	Yes
Secondary	Time spent in target range	CTR will improve (non-significantly at the projected sample size of N=5 subjects/site) the time spent within the target range of 80-140 mg/dL overnight (computed from retrofitted CGM data) and will reduce the extent of postprandial glucose excursions during the day. These data will provide justification and design support for a subsequent larger multi-center trial of CTR at home.	40 hours	Yes